PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders
Subject to certain conditions, the distribution by PDL will be made on the distribution date in the form of a pro rata common stock dividend to PDL stockholders of record as of the close of business on the record date. No fractional shares of Evofem common stock will be distributed. Instead, PDL stockholders will receive cash in lieu of any fraction of a share of Evofem common stock that they otherwise would have received. PDL stockholders should consult their tax advisors with respect to
An information statement describing the distribution will be included as an exhibit to a Current Report on Form 8-K filed by PDL with the
Additional information on the distribution, including a copy of the information statement, will be posted to PDL's website at http://investor.pdl.com/evofem-distribution-and-tax-information.
Throughout its history, PDL's mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies.
For more information please visit https://www.pdl.com/
Phexxi™ and Multipurpose Vaginal pH Regulator (MVP-R™) are trademarks of
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including as it relates to the Company's proposed Evofem stock distribution and plan of liquidation. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's assets and business, including the implementation or success of the Company's monetization strategy/plan of complete liquidation, are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q, filed with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-declares-distribution-ratio-for-dividend-of-evofem-biosciences-common-stock-to-pdl-stockholders-301061072.html
Jody Cain, LHA Investor Relations, 310-691-7100, firstname.lastname@example.org